Snowden Capital Advisors LLC Has $2.69 Million Stock Holdings in CVS Health Co. (NYSE:CVS)

Snowden Capital Advisors LLC decreased its position in shares of CVS Health Co. (NYSE:CVS - Free Report) by 16.5% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 60,001 shares of the pharmacy operator's stock after selling 11,880 shares during the period. Snowden Capital Advisors LLC's holdings in CVS Health were worth $2,693,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Park Avenue Securities LLC increased its position in shares of CVS Health by 5.8% during the 4th quarter. Park Avenue Securities LLC now owns 24,646 shares of the pharmacy operator's stock valued at $1,106,000 after purchasing an additional 1,359 shares during the period. Empirical Asset Management LLC boosted its stake in shares of CVS Health by 816.4% during the 4th quarter. Empirical Asset Management LLC now owns 36,885 shares of the pharmacy operator's stock worth $1,656,000 after acquiring an additional 32,860 shares in the last quarter. Avanza Fonder AB bought a new stake in CVS Health during the 4th quarter valued at approximately $4,745,000. HB Wealth Management LLC raised its position in shares of CVS Health by 12.7% during the fourth quarter. HB Wealth Management LLC now owns 20,029 shares of the pharmacy operator's stock valued at $899,000 after buying an additional 2,262 shares during the last quarter. Finally, Clarius Group LLC lifted its holdings in shares of CVS Health by 41.0% during the 4th quarter. Clarius Group LLC now owns 5,116 shares of the pharmacy operator's stock worth $230,000 after acquiring an additional 1,487 shares during the period. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Price Performance

CVS traded down $0.40 during trading on Friday, hitting $59.82. The company's stock had a trading volume of 2,118,376 shares, compared to its average volume of 11,335,510. The business's fifty day simple moving average is $66.28 and its 200 day simple moving average is $59.37. CVS Health Co. has a twelve month low of $43.56 and a twelve month high of $72.51. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80. The firm has a market capitalization of $75.68 billion, a price-to-earnings ratio of 16.31, a P/E/G ratio of 0.98 and a beta of 0.60.

CVS Health (NYSE:CVS - Get Free Report) last posted its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.63. The business had revenue of $94.59 billion for the quarter, compared to analysts' expectations of $93.07 billion. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The business's revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.31 earnings per share. On average, equities research analysts forecast that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd were paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 4.45%. The ex-dividend date was Tuesday, April 22nd. CVS Health's dividend payout ratio (DPR) is 63.48%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on CVS. JPMorgan Chase & Co. lifted their price target on shares of CVS Health from $80.00 to $81.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 18th. Evercore ISI boosted their target price on shares of CVS Health from $60.00 to $65.00 and gave the company an "outperform" rating in a research report on Monday, January 27th. Mizuho increased their price target on shares of CVS Health from $70.00 to $76.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 9th. Leerink Partners raised CVS Health from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $55.00 to $75.00 in a report on Thursday, February 13th. Finally, Edward Jones upgraded shares of CVS Health from a "hold" rating to a "buy" rating in a research note on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, CVS Health presently has an average rating of "Moderate Buy" and a consensus price target of $74.94.

Insider Activity

In other news, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the transaction, the senior vice president now directly owns 8,394 shares in the company, valued at approximately $556,941.90. The trade was a 47.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.22% of the company's stock.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.